Moclobemide (Manerix - Roche), the first of a new class of antidepressant drugs, was launched in the UK last year. It is a reversible inhibitor of monoamine oxidase A, which the manufacturer claims is a "first line treatment for major depression". Is this claim justified?
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.